Finance

Lists
CMPX:NASDAQ
Compass Therapeutics Inc.
$2.15
+8.04%
(+0.16) 1D
$2.16
+0.47% (+0.0100)
After hours
Closed: Aug 7, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CMPX...
Open
$2.05
High
$2.18
Low
$2.03
Mkt. cap
387.19M
Avg. vol.
2.90M
Volume
3.83M
52-wk high
$6.88
52-wk low
$1.61
EPS
-$0.41
Beta
0.77
Shares outstanding
180.09M
No. of employees
39
Open
$2.05
High
$2.18
Low
$2.03
Mkt. cap
387.19M
Avg. vol.
2.90M
Volume
3.83M
52-wk high
$6.88
52-wk low
$1.61
EPS
-$0.41
Beta
0.77
Shares outstanding
180.09M
No. of employees
39
News stories
From sources across the web
About Compass Therapeutics Inc.
CEO-
Employees39
Founded2014
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websitecompasstherapeutics.com
Analyst ratings
Based on 7 analysts giving stock ratings to CMPX in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for CMPX in the last 3 months.
Highest
Current $2.15
$24.00 (+1,016.28%)
Average
$9.33 (+333.95%)
Lowest
$6.00 (+179.07%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Newman
Canaccord Genuity
Buy
Reiterated
$7.00
+225.6%
08/07/2026
Biren Amin
Piper Sandler
Buy
Maintained
$6.00
+179.1%
08/07/2026
Andrew Berens
Leerink Partners
Buy
Maintained
$7.00
+225.6%
08/07/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
08/07/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
$6.00
+179.1%
08/06/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$24.00
+1,016.3%
08/06/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$6.00
+179.1%
06/01/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
-
-
05/06/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$8.00
+272.1%
05/06/2026
Sean McCutcheon
Raymond James
Hold
Downgraded
-
-
04/28/2026
Maury Raycroft
Jefferies
Buy
Maintained
$9.00
+318.6%
04/27/2026
Jonathan Chang
Leerink Partners
Buy
Maintained
$11.00
+411.6%
04/27/2026
Unknown Analyst
Wedbush
Buy
Reiterated
$8.00
+272.1%
03/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
12.83M
13.67M
13.39M
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.99M
4.32M
6.91M
-
Operating expense
15.82M
17.99M
20.30M
-
Total operating expenses
15.82M
17.99M
20.30M
-
Operating income
-15.82M
-17.99M
-20.30M
-
Other non operating income
-
-
-
-
EBT including unusual items
-14.26M
-15.72M
-18.32M
-
EBT excluding unusual items
-14.26M
-15.72M
-18.32M
-
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-14.26M
-15.72M
-18.32M
-
Net profit margin
-
-
-
-
Earnings per share
-0.08
-0.09
-0.10
-0.13
Interest and investment income
1.56M
2.27M
1.98M
-
Interest expense
-
-
-
-
Net interest expenses
1.56M
2.27M
1.98M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-15.80M
-17.97M
-20.28M
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps